The aging of the Western population is increasing the incidence of neurodegenerative diseases and the burden of patient care and medication on families and on governmental budgets. Current drug treatments are essentially symptomatic, and none is able to prevent, halt or much less reverse the neurodegenerative process. Alzheimer's disease probably has multiple causes. Epigenetic changes in the brain can have very significant effects on neurodegeneration and it has been shown that epigenetic changes can affect synaptic plasticity in different animals. ORY-2001 is an LSD1-MAOB inhibitor. LSD1, is a chromatin modulator that demethylates di- and monomethylated H3K4. In the CNS, LSD1 has been involved in the regulation of expression of neuronal genes and neurogenesis. MAO-B, plays an important role in the catabolism of neuroactive and vasoactive amines in the CNS and in peripheral tissues and is responsible for dopamine degradation. MAO-B is a well known target for Parkinson's Disease and has been explored in AD. LSD1 inhibitors are already in clinical trials in cancer but this is the first time they are promoted to clinical studies in CNS disorders. ORY-2001 improves memory in a mouse model for accelerated aging and Alzheimer's disease. The compound provokes changes in gene expression in the hippocampus; reduces the expression of inflammation and increases genes described to have a beneficial impact on memory. ORY-2001 has succesfully finalized preclinical toxicology studies and we have applied for authorization to start the first Phase I study. Here, we propose to evaluate if the molecular changes in the mouse brain can also be observed in humans, and if the effect of ORY-2001 in humans can be monitored measuring these changes. We believe this could accelerate the process of drug development, and help us to identify those patients that could benefit most from treatment with ORY-2001.